EUnetHTA Joint Action 3 (2016-20)

Home  /  Outputs   /  EUnetHTA Joint Action 3 (2016-20) (Page 2)

We are pleased to announce that the collaborative rapid assessment of JA3 WP4 on “ANTIBACTERIAL-COATED SUTURES VERSUS NON-ANTIBACTERIAL-COATED SUTURES FOR THE PREVENTION OF ABDOMINAL, SUPERFICIAL AND DEEP INCISIONAL, SURGICAL SITE INFECTION (SSI)” is available. Surgical site infection (SSI) is a

Final Assessment Report, External Comments/Answers and Project Plan for pharma JA on Regorafenib (Stivarga©) The purpose of the assessment is to evaluate Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously

Final Assessment Report, External Comments/Answers and Project Plan for pharma JA on midostaurin (Rydapt©) This is the assessment of the relative effectiveness of midostaurin (Rydapt©) in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy for patients in